ABBOTT INDIA LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: Private

Established: 1888-01-01

Employees: 73K

Market Cap: $7.5B

Website: http://www.abbott.com

Clinical Trials

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Biological: Adalimumab

First Posted Date: 2006-12-11

Last Posted Date: 2011-08-04

Lead Sponsor: Abbott

Target Recruit Count: 192

Registration Number: NCT00409682

Locations: 🇺🇸
Site Reference ID/Investigator# 4316, Chicago, Illinois, United States
🇺🇸
Site Reference ID/Investigator# 4317, Baltimore, Maryland, United States
🇺🇸
Site Reference ID/Investigator# 10287, Los Angeles, California, United States

and more 42 locations

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis

Phase 3

Completed

Conditions: Ulcerative Colitis

Interventions: Biological: adalimumab
Biological: placebo

First Posted Date: 2006-12-07

Last Posted Date: 2011-05-03

Lead Sponsor: Abbott

Target Recruit Count: 518

Registration Number: NCT00408629

Locations: 🇺🇸
Site Ref # / Investigator 3739, Atlanta, Georgia, United States
🇳🇴
Site Ref # / Investigator 5197, Oslo, Norway
🇳🇴
Site Ref # / Investigator 6297, Oslo, Norway

and more 105 locations

A Study Comparing Vicodin® CR and NORCO® to Placebo in Subjects With Acute Pain Following Bunionectomy

Phase 2

Completed

Conditions: Pain

Interventions: Drug: Hydrocodone/Acetaminophen Extended-Release
Drug: Hydrocodone/Acetaminophen Immediate Release (NORCO®)
Drug: Placebo

First Posted Date: 2006-11-28

Last Posted Date: 2011-07-25

Lead Sponsor: Abbott

Target Recruit Count: 90

Registration Number: NCT00404222

A Study Comparing the Analgesic Activity of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) and Placebo in Subjects With Pain Following Bunionectomy Surgery

Phase 2

Completed

Conditions: Pain

Interventions: Drug: Hydrocodone/Acetaminophen Extended Release
Drug: Placebo

First Posted Date: 2006-11-28

Last Posted Date: 2011-01-19

Lead Sponsor: Abbott

Target Recruit Count: 210

Registration Number: NCT00404391

Locations: 🇺🇸
Site Ref # / Investigator 4993, Owing Mills, Maryland, United States
🇺🇸
Site Ref # / Investigator 4994, Austin, Texas, United States
🇺🇸
Site Ref # / Investigator 4995, Salt Lake City, Utah, United States

and more 1 locations

A Study Comparing the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR)and Placebo in Subjects With Osteoarthritis

Phase 2

Completed

Conditions: Pain

Interventions: Drug: Extended-Release Hydrocodone/Acetaminophen
Drug: Placebo

First Posted Date: 2006-11-28

Last Posted Date: 2011-01-19

Lead Sponsor: Abbott

Target Recruit Count: 120

Registration Number: NCT00404183

A Study of Extended-Release Hydrocodone/Acetaminophen (Vicodin CR®) in Subjects With Acute Pain Following Bunionectomy

Phase 3

Completed

Conditions: Pain

Interventions: Drug: Hydrocodone/Acetaminophen Extended Release
Drug: Placebo
Drug: Hydrocodone/Acetaminophen Extended-Release

First Posted Date: 2006-11-22

Last Posted Date: 2011-01-25

Lead Sponsor: Abbott

Target Recruit Count: 150

Registration Number: NCT00402792

Locations: 🇺🇸
Site Ref # / Investigator 2587, Houston, Texas, United States
🇺🇸
Site Ref # / Investigator 2588, San Marcos, Texas, United States
🇺🇸
Site Ref # / Investigator 2586, San Antonio, Texas, United States

and more 2 locations

A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder

Phase 3

Completed

Conditions: Binge Eating Disorder
Obesity

First Posted Date: 2006-11-22

Last Posted Date: 2007-08-31

Lead Sponsor: Abbott

Target Recruit Count: 304

Registration Number: NCT00402584

A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine Insufficiency

Phase 3

Completed

Conditions: Pancreatic Exocrine Insufficiency, Chronic Pancreatitis, Pancreatectomy

Interventions: Drug: SA-001

First Posted Date: 2006-11-17

Last Posted Date: 2011-08-01

Lead Sponsor: Abbott

Target Recruit Count: 80

Registration Number: NCT00401076

Locations: 🇯🇵
Site Reference ID/Investigator# 45220, Hiroshima, Japan
🇯🇵
Site Reference ID/Investigator# 45213, Kanagawa, Japan
🇯🇵
Site Reference ID/Investigator# 45282, Miyagi, Japan

and more 14 locations

A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency

Phase 3

Completed

Conditions: Exocrine Pancreatic Insufficiency, Chronic Pancreatitis

Interventions: Drug: SA-001
Drug: Placebo

First Posted Date: 2006-11-17

Last Posted Date: 2011-07-28

Lead Sponsor: Abbott

Target Recruit Count: 274

Registration Number: NCT00400842

Locations: 🇯🇵
Site Reference ID/Investigator# 59984, Amori, Japan
🇯🇵
Site Reference ID/Investigator# 59572, Fukuoka, Japan
🇯🇵
Site Reference ID/Investigator# 59845, Aichi, Japan

and more 95 locations

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 2

Completed

Conditions: Attention-Deficit/Hyperactivity Disorder

Interventions: Drug: Placebo
Drug: ABT-089

First Posted Date: 2006-10-24

Last Posted Date: 2011-10-18

Lead Sponsor: Abbott

Target Recruit Count: 221

Registration Number: NCT00391729

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy